PBS listings to support patients with mesothelioma

From July 1, thousands of Australians and their families suffering from rare cancers and genetic disorders are set to benefit from expanded listings on the Pharmaceutical Benefits Scheme (PBS).   We are expanding the listing for Opdivo® and Yervoy® (nivolumab and ipilimumab), for the treatment of patients with unresectable malignant mesothelioma.   Unresectable malignant mesothelioma…

PBS Listings to Support Patients With Mesothelioma

From July 1, thousands of Australians and their families suffering from rare cancers and genetic disorders are set to benefit from expanded listings on the Pharmaceutical Benefits Scheme (PBS).   We are expanding the listing for Opdivo® and Yervoy® (nivolumab and ipilimumab), for the treatment of patients with unresectable malignant mesothelioma.   Unresectable malignant mesothelioma…